effect = 0.47%
A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study was done to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of orforglipron
All applications are for research purposes only
MyFitnessPal introduced tools supporting GLP-1 users with nutrition guidance, while Wisp partnered with Nourish to combine weight care programs with insurance-covered nutrition counseling
Key Findings Zepbound users noted hypertension concerns: Hypertension appeared more frequently in discussions of this newer tirzepatide brand (0.73% of posts)
Researchers are actively studying Retatrutide for its potential to support significant body fat reduction, enhanced insulin sensitivity, appetite control, and overall metabolic wellness